Researchers sought to determine whether primary anti-infectious prophylaxis would reduce the incidence of febrile neutropenia and treatment interruptions in older patients with iBC-NHLs.

Adding osimertinib to platinum-based chemotherapy may improve outcomes in patients with EGFR-mutant, advanced NSCLC who had disease progression on first-line osimertinib.

A phase 2 trial evaluated the combination of neoadjuvant pembrolizumab and accelerated methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in patients with nonurothelial bladder cancers ...

One in every 8 men in the United States will develop prostate cancer, according to prostate cancer statistics released by the American Cancer Society.

Survival rates also are lower for Black versus White people across various cancer types and categories of urbanicity.

Researchers sought to determine whether elranatamab would lead to durable responses in patients with relapsed or refractory multiple myeloma.

The effectiveness of the Interaktor app was evaluated in a randomized trial of patients undergoing radiotherapy for prostate cancer monitor and manage their symptoms.

Lower mortality risk seen for those who improved guideline concordance after diagnosis or maintained high concordance.

Researchers conducted a retrospective cohort study to assess the prevalence of normal thyroid function 3 years post-thyroidectomy among patients with thyroid cancer.

African American (AA) individuals with chronic lymphocytic leukemia (CLL) may have more high-risk features and unique genomic characteristics compared with European patients.